Conditions: Mild Cognitive Impairment Mild Alzheimer's Disease
Keywords: Mild Cognitive Impairment Mild Alzheimer's disease Safety Tolerability
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 164
Healthy volunteers: no

Brief summary:
This is a study where AZD5213 or placebo is given to patients with Mild Alzheimer's Disease or Mild Cognitive Impairment in a blinded and random assignment. The main study objective is to estimate the relationship of sleep duration versus dose after 4 weeks of treatment.

Detailed description:
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study

Arms:
arm 1: AZD5213 doseA daily arm 2: AZD 5213 doseB daily arm 3: AZD5213 doseC daily arm 4: Placebo daily

Interventions: intervention 1: AZD5213 intervention 2: AZD5213 intervention 3: AZD5213 intervention 4: Placebo
Intervention descriptions: intervention 1: AZD5213 doseA daily intervention 2: AZD5213 doseB daily intervention 3: AZD5213 doseC daily intervention 4: Placebo tablet daily

Protocol document: